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Abstract
Background—Alzheimer’s disease (AD) research progress is impeded due to participant 
recruitment challenges. This study seeks to better understand, from the perspective of individuals 
engaged in clinical trials (CTs), research motivations.
Methods—Participants, or their caregivers, from AD treatment and prevention CTs were 
surveyed about research motivators.
Results—The eighty-seven respondents had a mean age of 72.2, were predominantly Caucasian, 
55.2% were male, and 56.3% had cognitive impairment. An overwhelming majority rated the 
potential to help themselves or a loved one and the potential to help others in the future as 
important motivators. Relatively few respondents were motivated by free healthcare, monetary 
rewards, or to make others happy.
Conclusions—Recruitment efforts should focus on the potential benefit for the individual, their 
loved ones, and others in the future rather than free healthcare or monetary rewards.
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Introduction
Today over five million Americans have Alzheimer’s disease (AD) and it is estimated that 
someone develops AD every 67 seconds in the United States. It is expected that by 2050 
there will be between 11 and 16 million individuals living with AD in the United States if 
we do not experience any breakthroughs in therapeutic development [1]. While symptomatic 
treatments are currently available, at present there are no options for disease modifying 
therapies that might alter the disease course. Researchers are working to develop new 
medications or strategies to prevent or treat AD, but recruitment of research participants 
remains a challenge [2].
Recruitment has historically been one of the largest impediments to successful clinical trials 
[3]. Currently, less than one third of trials achieve their initial recruitment target and even 
among those trials that do reach their desired participation numbers, half require a prolonged 
recruitment period [4]. Improving the science behind recruitment for AD clinical trials is 
imperative for advancing the rate of scientific discoveries for prevention and treatment [5]. 
Challenges to the recruitment of AD clinical trials include fear of medication side-effects, 
perceived lack of personal benefit of placebo-controlled trials and in prevention studies, fear 
over invasive procedures, the requirement of a study partner, logistical concerns such as time 
and travel, general skepticism towards research, and for treatment focused trials the under-
diagnosis of AD and mild cognitive impairment [6]. While knowledge of these challenges 
can help inform study design to make trials more appealing to participants, addressing 
barriers does not guarantee that someone will chose to get involved. Much of the existing 
research exploring recruitment for clinical trials focuses on hypothetical research studies 
rather than real research participants [7]. In order to truly understand how to get individuals 
involved we need to better understand the motivations of participants who make the decision 
to enroll. Accordingly the purpose of this study is to better understand, from the perspective 
of individuals actually engaged in AD prevention and treatment clinical trials, motivations 
for research participation.
Methods
Surveys were mailed to 171 participants or their study partners from seven different AD 
prevention or treatment clinical trials being conducted at a single AD center. These studies 
included two for individuals with AD, two for individuals with mild cognitive impairment 
(MCI) or AD, one only for individuals with mild cognitive impairment, one for individuals 
with normal cognition or mild cognitive impairment, and one only for those with normal 
cognition. Surveys were mailed to active study participants, those who enrolled in one of the 
studies did not pass the screening process, and those who withdrew from one of the studies 
but agreed to be contacted about additional research. The surveys included a series of 
questions about potential motivators for research participation (e.g. to help themselves, to 
help others, to get free healthcare) and participants were asked to rate each item on a five-
point Likert scale from “not at all important” to “extremely important”. Responses were 
dichotomized to distinguish participants who rated a motivator as somewhat or extremely 
important from those that did not view that motivator as important. Analysis involved 
descriptive statistics to describe characteristics of the sample. Independent samples t-tests 
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and chi-square tests were done to explore differences based on group characteristics (e.g. 
respondents and non-respondents, normal and impaired cognition, women and men). In 
addition, Mann-Whitney tests were used to examine the non-dichotomized ordinal 
responses.
Results
Surveys were completed by 87 of the 171 respondents, representing a 51.2% response rate. 
There were no significant differences between respondents and non-respondents in terms of 
cognitive status, sex, race, or age (see Table 1).
The majority of surveys were completed by the research participant themselves (78.2%), 
with an average age of 72.4 (range of 54.6-89.8), just over half were male (55.2%), most 
were Caucasian (87.4%), and just over half were in a study for participants with cognitive 
impairment (MCI or AD) (56.3%) (See Table 2).
There were no significant differences between those with normal and impaired cognition in 
terms of sex, race, or age.
An overwhelming majority of respondents rated the potential to help themselves or a loved 
one (92.9%) and the potential to try to help others in the future (96.5%) as important 
motivators for research participation. Relatively few respondents were motivated by free 
healthcare services (23%) or monetary rewards (4.6%). A minority of participants indicated 
being motivated to make a family member (26.7%) or doctor (15.1%) happy (see Figure 1).
Women (38.5%) were significantly more likely than men (17.0%) to report participating in 
research to make family members happy, p=.025. There were no significant differences 
between those with normal and impaired cognition for any of the potential research 
motivators. There were also no significant age or racial differences in motivational factors 
based on whether the participant or study partner completed the survey.
Using Mann-Whitney statistics to explore the ranked responses, there were no statistically 
significant differences in motivational factors for participating based on the cognitive status 
or the race of the participant. Consistent with the dichotomized results, women rated the 
likelihood of participating to make a family member happy as more important than men, 
Mann–Whitney U = 697.0, n1 =47 n2 = 39, P =.049, two-tailed. Women also rated the 
likelihood of participating to make a doctor happy as more important than men, Mann–
Whitney U = 668.5, n1 =47 n2 = 39, P =.025, two-tailed (see Figure 2).
Finally, those who completed the survey themselves rated the desire to help themselves as 
lower than those who completed the survey on behalf of the research participant, Mann–
Whitney U = 364.0, n1 =66 n2 = 16, P =.024 two-tailed.
Discussion
The results of this study suggest that recruitment efforts for AD prevention and treatment 
clinical trials should focus on the potential benefit for the individual, their loved ones, and 
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others in the future rather than personal benefits such as free healthcare or monetary 
rewards. Efforts should be made to convey the message that research has the potential to 
help not only the individual involved, but also to help others in the future. The potential to 
help others in the future may be a particularly critical message to convey as many AD 
prevention and treatment research studies provide no clear immediate personal benefit, yet 
still entail invasive study procedures such as spinal fluid collection.
In addition, these findings suggest that future recruitment efforts should explore ways to 
leverage social awareness and the need to promote research participation, particularly among 
women. Given that most AD prevention and treatment research includes a study partner, 
efforts to engage various care partners and life companions, including spouses, adult 
children, partners or friends, and promote understanding of the importance of research 
participation across these individuals and across ages and racial groups may strengthen both 
recruitment and retention efforts [8]. Potential study partners may encourage their loved 
ones to participate in research based on the hope it will help their loved one directly. While 
the potential benefits of the treatments or interventions under investigation cannot be 
guaranteed, efforts to promote additional recruitment could highlight other possible benefits 
that participants may receive, including the close medical monitoring of individuals engaged 
in research studies and the personal fulfillment of playing a valuable role in the search for 
better ways to prevent or treat AD.
While this research was limited by a small sample size, one strength of this study is that 
responses come from research participants actually engaged in AD research, not from those 
being asked about hypothetical reasons they may choose to participate in research studies. 
The small sample size, however, may have prevented us from detecting differences in 
motivation for research engagement between different groups of participants. Future 
research should involve a larger, multi-site sample to explore whether motivations to 
participate in AD research may differ between participants and caregivers. Identifying 
potential differences in motivation along the cognitive continuum of participants may help to 
craft messages and target recruitment materials more effectively. While prior research has 
indicated how sociodemographic factors impact clinical trial eligibility, more work is needed 
to understand how these factors relate to willingness to participate [9]. Future research 
should gather a wider range of sociodemographic factors such as educational attainment and 
social support to better understand the nuances of research engagement. In addition, a larger 
sample should focus on expanding knowledge about the motivations for research 
participation among minority populations, who are largely underrepresented in AD research 
[10].
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Figure 1. 
Motivations for Participation – Self and Other Respondents
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Figure 2. 
Gender Differences in Research Motivations
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Table 1
Characteristics of Respondents and Non-Respondents
Respondents
n=87, n(%)
Non-Respondents
n=83, n(%)
Cognitive Status
 Normal 38 (43.7) 34 (41.0)
 Impaired 49 (56.3) 49 (59.)
Sex
 Male 48 (55.2) 39 (47.0)
 Female 39 (44.8) 44 (53.0)
Race
 Caucasian 76 (87.4) 71 (85.5)
 Other 11 (12.6) 12 (14.5)
Age, mean (SD) 72.4 (7.4) 73.2 (7.2)
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Table 2
Respondent Characteristics
Normal Cognition
n=38, n(%)
Impaired Cognition
n=49, n(%)
All Respondents
n=87, n(%)
Respondent
 Participant 37 (97.4) 31 (63.3) 68 (78.2)
 Study Partner 1 (2.6) 15 (30.6) 16 (18.4)
 Unknown 0 3 (6.1) 3 (3.4)
Sex
 Male 20 (52.6) 28 (57.1) 48 (55.2)
 Female 18 (47.4) 21 (42.9) 39 (44.8)
Race
 Caucasian 32 (84.2) 44 (89.8) 76 (87.4)
 Other 6 (15.8) 5 (10.2) 11 (12.6)
Age, mean (SD) 72.2 (4.5) 72.5 (9.1) 72.4 (7.4)
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